Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
2000 1
2002 1
2004 1
2005 1
2007 3
2008 4
2009 2
2010 2
2011 3
2012 4
2013 3
2014 9
2015 11
2016 11
2017 22
2018 17
2019 22
2020 16
2021 23
2022 19
2023 19
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Differentiated Thyroid Gland Carcinoma"
Page 1
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Schlumberger M, et al. N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470. N Engl J Med. 2015. PMID: 25671254 Free article. Clinical Trial.
BACKGROUND: Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor alpha, RET, and KIT, showed clinical activity in a phase 2 study involving patients with …
BACKGROUND: Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 …
Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R, Fogarty CE, Ma B, Li H, Ni G, Liu X, Yuan J, Wang T. Lin R, et al. BMC Genomics. 2021 Jul 27;22(1):576. doi: 10.1186/s12864-021-07895-6. BMC Genomics. 2021. PMID: 34315405 Free PMC article.
BACKGROUND: Papillary thyroid carcinoma (PTC) is the most common thyroid cancer. While many patients survive, a portion of PTC cases display high aggressiveness and even develop into refractory differentiated thyroid carcinoma. ... …
BACKGROUND: Papillary thyroid carcinoma (PTC) is the most common thyroid cancer. While many patients survive, a portion …
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, Benisvy D, Taïeb D, Bardet S, Terroir-Cassou-Mounat M, Anizan N, Bouvier-Morel E, Lamartina L, Lion G, Betrian S, Sajous C, Schiazza A, Garcia ME, Ciappuccini R, Schlumberger M, Al Ghuzlan A, Godbert Y, Borget I. Leboulleux S, et al. Clin Cancer Res. 2023 Jul 5;29(13):2401-2409. doi: 10.1158/1078-0432.CCR-23-0046. Clin Cancer Res. 2023. PMID: 37074727 Clinical Trial.
PURPOSE: To evaluate the efficacy and safety of dabrafenib-trametinib-131I for the treatment of radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) with a BRAF p.V600E mutation. ...Ten patients received a second treatment course: one …
PURPOSE: To evaluate the efficacy and safety of dabrafenib-trametinib-131I for the treatment of radioactive iodine refractory metasta …
Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Haddad R, Elisei R, Hoff AO, Liu Z, Pitoia F, Pruneri G, Sadow PM, Soares F, Turk A, Williams MD, Wirth LJ, Cabanillas ME. Haddad R, et al. JAMA Oncol. 2023 Aug 1;9(8):1132-1141. doi: 10.1001/jamaoncol.2023.1379. JAMA Oncol. 2023. PMID: 37289450 Review.
IMPORTANCE: Thyroid epithelial malignant neoplasms include differentiated thyroid carcinomas (papillary, follicular, and oncocytic), follicular-derived high-grade thyroid carcinomas, and anaplastic and medullary thyroid carcinomas, with a …
IMPORTANCE: Thyroid epithelial malignant neoplasms include differentiated thyroid carcinomas (papillary, follicu …
Redifferentiation of Differentiated Thyroid Cancer: Clinical Insights from a Narrative Review of Literature.
Van Nostrand D, Veytsman I, Kulkarni K, Heimlich L, Burman KD. Van Nostrand D, et al. Thyroid. 2023 Jun;33(6):674-681. doi: 10.1089/thy.2022.0632. Epub 2023 Mar 21. Thyroid. 2023. PMID: 36792922 Review.
Background: Patients who have metastatic differentiated thyroid cancer (mDTC) frequently have negative diagnostic and/or post-therapy radioiodine scans. ...Further studies are warranted to confirm these preliminary observations and to confirm acceptable subse …
Background: Patients who have metastatic differentiated thyroid cancer (mDTC) frequently have negative diagnostic and/or post- …
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
Lin Y, Qin S, Yang H, Shi F, Yang A, Han X, Liu B, Li Z, Ji Q, Tang L, Deng Z, Ding Y, Fu W, Xie X, Li L, He X, Lv Z, Ma Q, Shen Z, Guo Z, Chen Z, Cui Y, Tan J, Gao Z, Jing S, Lu K, Luo X, Zhang Y, Fang Y, Li Z, Cheng Y, Lei S, Luan S, Chen G, Wang G, Wu L, Liu L. Lin Y, et al. Clin Cancer Res. 2023 Aug 1;29(15):2791-2799. doi: 10.1158/1078-0432.CCR-22-3613. Clin Cancer Res. 2023. PMID: 37184934 Clinical Trial.
PURPOSE: The phase II/III study of donafenib was initiated when there was no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibit …
PURPOSE: The phase II/III study of donafenib was initiated when there was no available treatment indicated for Chinese patients with progres …
MicroRNAs in thyroid development, function and tumorigenesis.
Fuziwara CS, Kimura ET. Fuziwara CS, et al. Mol Cell Endocrinol. 2017 Nov 15;456:44-50. doi: 10.1016/j.mce.2016.12.017. Epub 2016 Dec 21. Mol Cell Endocrinol. 2017. PMID: 28011236 Review.
Loss of thyroid cell differentiation/function, and consequently iodine trapping impairment, is an important clinical characteristic of radioiodine-refractory thyroid cancer. However, few studies have addressed the direct role of miRNAs in thy …
Loss of thyroid cell differentiation/function, and consequently iodine trapping impairment, is an important clinical ch …
Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy.
Boucai L, Saqcena M, Kuo F, Grewal RK, Socci N, Knauf JA, Krishnamoorthy GP, Ryder M, Ho AL, Ghossein RA, Morris LGT, Seshan V, Fagin JA. Boucai L, et al. Clin Cancer Res. 2023 Apr 14;29(8):1620-1630. doi: 10.1158/1078-0432.CCR-22-2882. Clin Cancer Res. 2023. PMID: 36780190 Free PMC article.
We aimed to identify genomic and transcriptomic factors associated with structural responses to RAI treatment of metastatic thyroid cancer, which occur infrequently, and to test whether high MAPK pathway output was associated with RAI refractoriness. ...RESULTS: ER …
We aimed to identify genomic and transcriptomic factors associated with structural responses to RAI treatment of metastatic thyroid c …
Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT, Cohen EE. Yeung KT, et al. Clin Cancer Res. 2015 Dec 15;21(24):5420-6. doi: 10.1158/1078-0432.CCR-15-0923. Epub 2015 Oct 20. Clin Cancer Res. 2015. PMID: 26487760 Review.
Management options are limited for patients with radioactive iodine refractory, locally advanced, or metastatic differentiated thyroid carcinoma. ...In this article, we will review the molecular mechanisms of lenvatinib, the data from preclinical studi …
Management options are limited for patients with radioactive iodine refractory, locally advanced, or metastatic differentiated …
A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.
Meng C, Song J, Long W, Mu Z, Sun Y, Liang J, Lin Y. Meng C, et al. Front Endocrinol (Lausanne). 2023 Feb 10;14:1109439. doi: 10.3389/fendo.2023.1109439. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36843580 Free PMC article.
BACKGROUND: The diagnosis of radioiodine refractory differentiated thyroid cancer (RAIR-DTC) is primarily based on clinical evolution and iodine uptake over the lesions, which is still time-consuming, thus urging a predictive model for timely RAIR-DTC …
BACKGROUND: The diagnosis of radioiodine refractory differentiated thyroid cancer (RAIR-DTC) is primarily based on clin …
174 results